BSG and severe acute respiratory syndrome: Pre-treatment with an antibody able to specifically block one of the several functions of CD147 (CyPA binding [17,23]), different from Meplazumab (used by Wang et al. [6]), did not affect SARS-CoV-2 entry, thus suggesting that the molecular mechanism underlying CD147 role might be different from the one reported for SARS-CoV infection.